The authors hypothesized that since the systemic delivery of the TRPV4 antagonist did not affect ventricle size in wild-type animals, the increased permeability of the various brain barriers due to the hydrocephalus allowed the drug to reach its target in the choroid plexus. Here, TRPV4 is linked to Hydrocephalus.